Physiomics (PYC.L)

Executive Summary

Physiomics is a UK-based consultancy that specializes in model-informed drug development (MIDD), biostatistics, statistical programming, and bioinformatics. Founded in 2001 and publicly traded on the London Stock Exchange (ticker: PYC.L), the company supports a wide range of clients—from emerging biotechs to top-tier pharma and research institutes—throughout the drug development continuum. Despite its long history and niche expertise, Physiomics operates at a pre-clinical stage with a modest valuation of approximately $2.4 million. The company leverages AI and machine learning to accelerate and de-risk drug development, offering data-driven solutions that improve efficiency and probability of success for its partners. With no disclosed products or proprietary pipelines, Physiomics' value is tied to its consulting revenue and ability to secure new contracts in a competitive landscape.

Upcoming Catalysts (preview)

• Q3 2026FY 2025 Full-Year Results Release100% success
• Q4 2026New Major Client or Partnership Agreement30% success
• Q4 2026Expansion of AI-Driven Service Offerings25% success